Mr. McGirr has served as a member of our Board of Directors since November 2015. Mr. McGirr serves as a director of Insmed Inc., a pharmaceutical company devoted to the treatment of rare diseases; Menlo Therapeutics Inc., focused on the development of serlopitant for the treatment of pruritus (itch) associated with various conditions; and X4 Pharmaceuticals Inc., which is developing therapeutics to improve immune cell trafficking to treat rare diseases. From March 2013 until June 2014, Mr. McGirr was Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals, and from November 2002 to March 2013, Mr. McGirr was Senior Vice President and Chief Financial Officer of Cubist. Prior to joining Cubist, Mr. McGirr was President and Chief Operating Officer of Hippo Inc., an Internet technology company, from 1999 to 2002, for which he also served as a director. He was President Chief Executive Officer of GAB Robins North America, Inc., a risk management company, from 1997 to 1999, where he had previously served as President from 1996 to 1997. Mr. McGirr was a private equity investor from 1995 to 1996. Prior to that, he served in various positions within the S.G. Warburg Group from 1978 to 1995, ultimately as Chief Financial Officer, Chief Administrative Officer, and Managing Director of S.G. Warburg & Co., Inc., a position he held from 1992 to 1995. Mr. McGirr received a BS in civil engineering from the University of Glasgow and an MBA from The Wharton School at the University of Pennsylvania.